DK2408807T3 - Fremgangsmåde til terapeutisk anvendelse - Google Patents

Fremgangsmåde til terapeutisk anvendelse Download PDF

Info

Publication number: DK2408807T3
Authority: DK; Denmark
Prior art keywords: therapeutic use; therapeutic
Prior art date: 2009-03-18

Application number

DK10710017.4T

Other languages

English (en)

Inventor

Andrea Pfeifer

Andreas Muhs

Maria Pihlgren

Original Assignee

Ac Immune Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-18

Filing date

2010-03-18

Publication date

2021-08-09

2010-03-18 Application filed by Ac Immune Sa filed Critical Ac Immune Sa

2021-08-09 Application granted granted Critical

2021-08-09 Publication of DK2408807T3 publication Critical patent/DK2408807T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Marine Sciences & Fisheries (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Physical Education & Sports Medicine (AREA)

DK10710017.4T 2009-03-18 2010-03-18 Fremgangsmåde til terapeutisk anvendelse DK2408807T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16116509P	2009-03-18	2009-03-18
US25602809P	2009-10-29	2009-10-29
PCT/EP2010/053519 WO2010106127A2 (en)	2009-03-18	2010-03-18	Method for therapeutic use

Publications (1)

Publication Number	Publication Date
DK2408807T3 true DK2408807T3 (da)	2021-08-09

Family

ID=42376556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10710017.4T DK2408807T3 (da)	2009-03-18	2010-03-18	Fremgangsmåde til terapeutisk anvendelse

Country Status (17)

Country	Link
US (1)	US20100285108A1 (da)
EP (2)	EP3978517A1 (da)
JP (2)	JP2012520852A (da)
KR (1)	KR20120004994A (da)
CN (1)	CN102428101B (da)
AU (1)	AU2010224824B2 (da)
CA (1)	CA2755683A1 (da)
DK (1)	DK2408807T3 (da)
ES (1)	ES2885398T3 (da)
HU (1)	HUE055739T2 (da)
IL (1)	IL214919A (da)
MX (1)	MX2011009654A (da)
PT (1)	PT2408807T (da)
RU (1)	RU2579659C2 (da)
SG (1)	SG174871A1 (da)
SI (1)	SI2408807T1 (da)
WO (1)	WO2010106127A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA107571C2 (xx)	2009-04-03	2015-01-26		Фармацевтична композиція
EP2440234A4 (en)	2009-06-10	2013-11-06	Univ New York	IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
MX338421B (es)	2010-10-07	2016-04-15	Ac Immune Sa	Anticuerpos fosfoespecificos que reconocen la proteina tau.
AU2013205313B2 (en) *	2010-10-07	2016-05-19	Ac Immune S.A.	Phosphospecific antibodies recognising tau
KR20160005380A (ko) *	2011-09-23	2016-01-15	에이씨 이뮨 에스.에이.	백신 요법
RU2639537C2 (ru) *	2011-10-07	2017-12-21	Ац Иммуне С.А.	Фосфоспецифичные антитела, распознающие тау
EP2834270B1 (en) *	2012-04-05	2019-10-30	AC Immune S.A.	Humanized tau antibody
JP6445427B2 (ja) *	2012-05-08	2018-12-26	ウエスタンユニバーシティオブヘルスサイエンシズ	ＣＤ４＋Ｔ細胞集団の抗原特異的な拡大のために標準化されたｅｘｖｉｖｏプラットフォーム
RU2661111C2 (ru)	2013-03-15	2018-07-11	Ац Иммуне С.А.	Антитела к тау и способы применения
US10132818B2 (en)	2014-07-08	2018-11-20	New York University	Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
KR102318994B1 (ko)	2015-01-23	2021-10-29	헬릭스 바이오파마 코포레이션	치료학적 목적을 위한 항체-우레아제 접합체
EP3334453A4 (en)	2015-08-13	2019-02-06	New York University	SPECIFIC ANTIBODY MOLECULES OF THE ASP421 EPITOPE TRUNCATED FROM THE TAU PROTEIN AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY
MA50465A (fr) *	2017-10-25	2020-09-02	Ac Immune Sa	Compositions de peptides tau phosphorylés et leurs utilisations
CA3129252A1 (en)	2019-02-08	2020-08-13	Ac Immune S.A.	Method of safe administration of phosphorylated tau peptide vaccine
BR112021021213A2 (pt)	2019-04-24	2021-12-21	Ac Immune Sa	Administração heteróloga de vacinas de tau

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7408027B1 (en) *	1991-12-06	2008-08-05	Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften	Tools for the diagnosis and treatment of Alzheimer's disease
ES2118373T3 (es) *	1992-12-14	1998-09-16	Innogenetics Nv	Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones.
US7427392B1 (en) *	1994-11-14	2008-09-23	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) *	1996-03-13	2002-07-04	Koichi Ishiguro	Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) *	1996-11-19	1998-05-28	The Wistar Institute Of Anatomy & Biology	Diagnostic and therapeutic reagents for alzheimer's disease
EP1301531A2 (en) *	2000-07-11	2003-04-16	Molecular Geriatrics Corporation	Reagents and methods for identification of binding agents
BR0317747A (pt)	2002-12-24	2005-11-22	Neurochem Int Ltd	Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
US8663650B2 (en) *	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
EP1494000A1 (en) *	2003-07-02	2005-01-05	Sicpa Holding S.A.	Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material
US20050261475A1 (en) *	2004-02-13	2005-11-24	Harvard Medical School	Solid-phase capture-release-tag methods for phosphoproteomic analyses
PT2465533E (pt) *	2004-02-20	2015-06-24	Ac Immune Sa	Processos e composições que têm estruturas supramoleculares
CN101330923B (zh) *	2005-12-12	2015-01-07	Ac免疫有限公司	治疗性疫苗
US8012936B2 (en) *	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
WO2008140639A2 (en) *	2007-02-08	2008-11-20	Oligomerix, Inc.	Biomarkers and assays for alzheimer's disease
UA107571C2 (xx) *	2009-04-03	2015-01-26		Фармацевтична композиція

2010
- 2010-03-18 PT PT107100174T patent/PT2408807T/pt unknown
- 2010-03-18 KR KR1020117024550A patent/KR20120004994A/ko not_active Application Discontinuation
- 2010-03-18 DK DK10710017.4T patent/DK2408807T3/da active
- 2010-03-18 EP EP21180474.5A patent/EP3978517A1/en active Pending
- 2010-03-18 HU HUE10710017A patent/HUE055739T2/hu unknown
- 2010-03-18 US US12/661,628 patent/US20100285108A1/en not_active Abandoned
- 2010-03-18 RU RU2011141889/10A patent/RU2579659C2/ru active
- 2010-03-18 MX MX2011009654A patent/MX2011009654A/es active IP Right Grant
- 2010-03-18 JP JP2012500251A patent/JP2012520852A/ja not_active Withdrawn
- 2010-03-18 SG SG2011067097A patent/SG174871A1/en unknown
- 2010-03-18 SI SI201032083T patent/SI2408807T1/sl unknown
- 2010-03-18 WO PCT/EP2010/053519 patent/WO2010106127A2/en active Application Filing
- 2010-03-18 ES ES10710017T patent/ES2885398T3/es active Active
- 2010-03-18 AU AU2010224824A patent/AU2010224824B2/en active Active
- 2010-03-18 CN CN201080021554.XA patent/CN102428101B/zh active Active
- 2010-03-18 EP EP10710017.4A patent/EP2408807B1/en active Active
- 2010-03-18 CA CA2755683A patent/CA2755683A1/en not_active Abandoned
2011
- 2011-09-01 IL IL214919A patent/IL214919A/en active IP Right Grant
2015
- 2015-07-06 JP JP2015134900A patent/JP2015221809A/ja active Pending

Also Published As

Publication number	Publication date
CA2755683A1 (en)	2010-09-23
AU2010224824A1 (en)	2011-09-22
RU2579659C2 (ru)	2016-04-10
CN102428101B (zh)	2016-03-02
SI2408807T1 (sl)	2021-11-30
PT2408807T (pt)	2021-09-03
WO2010106127A3 (en)	2011-03-31
ES2885398T3 (es)	2021-12-13
RU2011141889A (ru)	2013-04-27
IL214919A (en)	2016-10-31
JP2015221809A (ja)	2015-12-10
HUE055739T2 (hu)	2021-12-28
AU2010224824B2 (en)	2014-02-20
AU2010224824A2 (en)	2011-09-22
SG174871A1 (en)	2011-11-28
IL214919A0 (en)	2011-11-30
EP2408807A2 (en)	2012-01-25
CN102428101A (zh)	2012-04-25
KR20120004994A (ko)	2012-01-13
US20100285108A1 (en)	2010-11-11
MX2011009654A (es)	2011-10-12
JP2012520852A (ja)	2012-09-10
WO2010106127A2 (en)	2010-09-23
EP3978517A1 (en)	2022-04-06
EP2408807B1 (en)	2021-07-21

Publication	Publication Date	Title
CY2017047I2 (el)	2018-04-04	Συνδυαστικη θεραπεια για χαπ
DK2408807T3 (da)	2021-08-09	Fremgangsmåde til terapeutisk anvendelse
BR112012004707A2 (pt)	2016-04-12	método
BR112012000624A2 (pt)	2016-02-10	método
FI20090389A0 (fi)	2009-10-23	Menetelmä
BR112012015988A2 (pt)	2017-06-06	método
ATE526024T1 (de)	2011-10-15	Fluvoxamin vermeidende pirfenidontheraphy
BRPI1012526A2 (pt)	2016-03-29	método
BRPI1010705A2 (pt)	2015-09-15	método
BRPI0917684A2 (pt)	2015-12-01	método terapêutico homeopático
DK2310613T3 (da)	2014-05-26	Forbedret brudled til stigrør
DK2513288T3 (da)	2014-06-23	Indretning til kontinuerlig dyrkning
BRPI1012532A2 (pt)	2016-03-29	método
BR112013009024A2 (pt)	2016-07-12	método
BR112012023891A2 (pt)	2017-12-05	método
BRPI1009350A2 (pt)	2016-03-08	método
ITPD20090053U1 (it)	2011-04-10	Paradordi per banchine
BRPI1013903A2 (pt)	2016-07-19	tratamentos terapêuticos utilizando centaquina
BR112013015580A2 (pt)	2016-10-04	método de radioestabilização
BR112012033000A2 (pt)	2015-09-15	método
ES1070798Y (es)	2010-01-22	Ataud
TH105556B (th)	2010-12-30	สารประกอบ และ วิธีการใหม่สำหรับการบำบัด
IT1396653B1 (it)	2012-12-14	Apparato
IT1396965B1 (it)	2012-12-20	Dispositivo terapeutico
ITCT20090003U1 (it)	2010-08-21	Telepass -2 per non udenti